The patient safety domain was assessed using 11 AHRQ Patient Safety Indicators (PSIs), also based on SPARCS data from 2014 obtained from the NYSDOH Open Data website [accessioned March 27, 2018, PSI version 6.0, September 2015]. The domain encompassed six measures of perioperative and postoperative adverse events. These events included postoperative hip fracture (PSI 08), perioperative hemorrhage or hematoma (PSI 09), postoperative physiologic and metabolic derangements (PSI 10), postoperative respiratory failure (PSI 11), perioperative pulmonary embolism or deep vein thrombosis (PSI 12), postoperative wound dehiscence (PSI 14), pressure ulcers (PSI 03), iatrogenic pneumothorax (PSI 06), central venous catheter-related bloodstream infection (PSI 07), accidental puncture or laceration (PSI 15), and deaths among patients with low-mortality diagnoses (PSI 02). These PSIs, except for PSI 10, are either NQF endorsed or included in the NQF endorsed composite PSI.
These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements, including without limitation, uncertainty of success in the development and potential commercialization of tofersen; the risk that we may not fully enroll our clinical trials or enrollment will take longer than expected; unexpected concerns may arise from additional data, analysis or results obtained during our clinical trials; regulatory authorities may require additional information or further studies, or may fail or refuse to approve or may delay approval of our drug candidates, including tofersen; the occurrence of adverse safety events; the risks of unexpected hurdles, costs or delays; failure to protect and enforce our data, intellectual property and other proprietary rights and uncertainties relating to intellectual property claims and challenges; product liability claims; and the direct and indirect impacts of the ongoing COVID-19 pandemic on our business, results of operations and financial condition. The foregoing sets forth many, but not all, of the factors that could cause actual results to differ from our expectations in any forward-looking statement. Investors should consider this cautionary statement, as well as the risk factors identified in our most recent annual or quarterly report and in other reports we have filed with the U.S. Securities and Exchange Commission. These statements are based on our current beliefs and expectations and speak only as of the date of this news release.
In 1984, the plant was manufacturing Sevin at one quarter of its production capacity due to decreased demand for pesticides. Widespread crop failures and famine on the subcontinent in the 1980s led to increased indebtedness and decreased capital for farmers to invest in pesticides. Local managers were directed to close the plant and prepare it for sale in July 1984 due to decreased profitability . When no ready buyer was found, UCIL made plans to dismantle key production units of the facility for shipment to another developing country. In the meantime, the facility continued to operate with safety equipment and procedures far below the standards found in its sister plant in Institute, West Virginia. The local government was aware of safety problems but was reticent to place heavy industrial safety and pollution control burdens on the struggling industry because it feared the economic effects of the loss of such a large employer .
You may receive a "Virus scan failed" or "Virus detected" error message when you try to open or save a file or a program from Internet. In most cases, it is not caused by the Windows operating system, but by the antivirus software. If you are certain that the source you are trying to open is safe and trusted, try the following workaround to disable the virus scanning temporarily, and then enable the virus scanning immediately after you complete downloading the program or file. You have to be very cautious about using this workaround. Otherwise, you may be exposed to virus attacks.
The Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward-looking statements made by us or on our behalf. This press release contains statements which constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Any statement that is not historical in nature is a forward-looking statement and may be identified by the use of words and phrases such as "expects," "anticipates," "believes," "will," "will likely result," "will continue," "plans to," "potential," "promising," and similar expressions. These statements are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those described in the forward-looking statements, including potential failure of RELIANCE trial results to demonstrate clinically significant evidence of efficacy and/or safety, failure of top-line results to accurately reflect the complete results of the trial, failure to obtain regulatory approval of REL-1017 for the treatment of major depressive disorder, and the other risk factors described under the heading "Risk Factors" set forth in the Company's reports filed with the SEC from time to time. No forward-looking statement can be guaranteed, and actual results may differ materially from those projected. Relmada undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise. Readers are cautioned that it is not possible to predict or identify all the risks, uncertainties and other factors that may affect future results and that the risks described herein should not be a complete list. 2b1af7f3a8